Deal-Making In 2023: Pharma Finds Value In Flexibility

Restricted financial avenues raised many open questions at the recent LSX World Congress about the kind of deals that will shape biopharma pipelines in the coming 12-18 months. 

Mergers

During a panel session at LSX World Congress in London, UK, on pharma business development and M&A in 2023 and beyond, four panellists from major pharma players broadly agreed that every deal needs flexibility on both sides to create the most value.

Chris Sheldon, SVP, global head of business development, said GlaxoSmithKline looked for three key things. The best deals, he said, were in the “intersection of great science, great financial...

More from Business Strategy

More from In Vivo